Pharmaceuticals DC $500K+ Reviewed

Barda Drive Ez-baa (ezbaa - 22-100-sol-00003)

HHS

WASHINGTON, DC

vaccines on demand host-directed therapeutics medical countermeasures lung therapeutics host diagnostics $500K+

Posted Dec 15, 2022

Due Oct 18, 2027

Description

The HHS BARDA DRIVe EZ-BAA (EZ-BAA-22-100-SOL-00003) solicits research and development proposals for innovative medical countermeasures across multiple Areas of Interest (AOIs), including ReDIRECT, Lab at Home, Digital MCMs, Host-Directed Therapeutics, Healing Lungs, DRIVe Forward, Vaccines on Demand, ReBooT, Host-Based Diagnostics, and REPAIR. These AOIs focus on advancing technologies for diagnostics, therapeutics, vaccines, and lung repair to enhance pandemic preparedness and response. Eligible bidders include biotech firms, pharmaceutical companies, academic researchers, and medical technology developers with expertise in these domains.

A strong match for healthcare vendors

Curated for medical & healthcare suppliers

Why we classified this as medical

BARDA (Biomedical Advanced Research and Development Authority) under HHS solicits R&D proposals for medical countermeasures via Areas of Interest like Vaccines on Demand, Host-Directed Therapeutics, Digital MCMs, and Healing Lungs, which directly target pharmaceuticals, vaccines, diagnostics, and therapeutics. The DRIVe initiative focuses on advancing biomedical technologies for public health emergencies, making this highly relevant to medical vendors in devices, drugs, and diagnostics.

View Original Source

Save for Later

Send to Pipeline

Closing date unconfirmed

This bid lists a closing date of Oct 18, 2027, which is more than a year out — almost certainly a data error from the source. Treat the deadline as unknown.

Please confirm the actual deadline on the original source before you rely on it.

Check the source